モデルナは、mRNA医薬品分野における革新的リーダーです。mRNA技術の進展を通して、モデルナは医薬品の製造方法を根本から変え、疾患の治療と予防へのアプローチを変革し続けています。モデルナは10年以上にわたって科学、技術、健康分野の研究に取り組んでお ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Newborns are at risk for serious complications from influenza infections but are not eligible for vaccination until they are ...

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a ...

「新型インフルエンザ」のパンデミックが起きた２００９年、私は米国アトランタのＣＤＣに赴き、ＡＣＩＰ会議に参加しました。ＡＣＩＰはＡｄｖｉｓｏｒｙ　Ｃｏｍｍｉｔｔｅｅ　ｏｎ　Ｉｍｍｕｎｉｚａｔｉｏｎ　Ｐｒａｃｔｉｃｅｓの頭文字を取ったものです。ワクチン ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...